[Rituximab (MabThera): a new therapy for ANCA vasculitis]. / Le médicament du mois. Rituximab (MabThera): nouveau médicament dans les vascularites associées á ANCA.
Rev Med Liege
; 70(2): 92-100, 2015 Feb.
Article
in Fr
| MEDLINE
| ID: mdl-26011994
ABSTRACT
Three recently published randomized studies have demonstrated the efficacy of rituximab in the induction and maintenance therapy of ANCA vasculitis. This is a major advance since these types of vasculitis entail a high morbity and mortality.
Search on Google
Collection:
01-internacional
Health context:
6_ODS3_enfermedades_notrasmisibles
Database:
MEDLINE
Main subject:
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
/
Antibodies, Monoclonal, Murine-Derived
Type of study:
Clinical_trials
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
Fr
Journal:
Rev Med Liege
Year:
2015
Document type:
Article